

Audit Review Table					
Blue Cross and Blue Shield of New Mexico, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company (Org ID: 1825, Sub ID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2025; Date & Timestamp - 6/3/2026 9:13:23 AM					
This submission is on the stage: Finalize Attestation					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		63.02%	R	R	Reported
Counseling for Nutrition (Total)		43.31%	R	R	Reported
Counseling for Physical Activity (Total)		44.04%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		53.77%	R	R	Reported
Chlamydia Screening (CHL)					
(Total)		47.71%	R	R	Reported
Oral Evaluation, Dental Services (OED)	Y				
(0-2)		25.01%	R	R	Reported
(3-5)		56.60%	R	R	Reported
(6-14)		60.48%	R	R	Reported
(15-20)		41.97%	R	R	Reported
(Total)		50.33%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		5.48%	R	R	Reported
(3-4)		6.01%	R	R	Reported
(Total)		5.74%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y				
(Total)		80.78%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y				
Systemic Corticosteroid		54.04%	R	R	Reported
Bronchodilator		64.60%	R	R	Reported
Asthma Medication Ratio (AMR)	Y				
(Total)		84.88%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		55.23%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack		50.00%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Received Statin Therapy (Total)		74.91%	R	R	Reported
Statin Adherence 80% (Total)		65.26%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Initiation (Total)		5.80%	R	R	Reported
Engagement1 (Total)		9.18%	R	R	Reported
Engagement2 (Total)		7.25%	R	R	Reported
Achievement (Total)		1.45%	R	R	Reported
Glycemic Status Assessment for Patients With Diabetes (GSD)					
Glycemic Status <8.0%		46.23%	R	R	Reported
Glycemic Status >9.0%		45.74%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		53.53%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		44.95%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
(Total)		36.65%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Received Statin Therapy		53.56%	R	R	Reported
Statin Adherence 80%		66.44%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
(Total)		31.69%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
30 days (Total)		69.65%	R	R	Reported
7 days (Total)		47.24%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
30 days (Total)		59.87%	R	R	Reported
7 days (Total)		42.91%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Alcohol (Total)		5.07%	R	R	Reported
Opioid (Total)		5.55%	R	R	Reported
Other (Total)		6.64%	R	R	Reported
Any (Total)		12.55%	R	R	Reported

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				
30 days (Total)		55.42%	R	R	Reported
7 Days (Total)		35.18%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
30 days (Total)		43.75%	R	R	Reported
7 days (Total)		29.55%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
(Total)		17.35%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		82.22%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		66.76%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia		90.00%	NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		56.84%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
(Total)		83.10%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
(Total)		49.95%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
(Total)		62.91%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
Use of Opioids at High Dosage		3.25%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
Multiple Prescribers		16.98%	R	R	Reported
Multiple Pharmacies		1.68%	R	R	Reported
Multiple Prescribers and Multiple Pharmacies		1.09%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
>=15 Days (Total)		5.14%	R	R	Reported
>=31 Days (Total)		3.90%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
(Total)		77.00%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
Initiation of SUD Treatment - Total (Total)		50.13%	R	R	Reported
Engagement of SUD Treatment - Total (Total)		19.11%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
Timeliness of Prenatal Care		80.54%	R	R	Reported
Postpartum Care		75.91%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
(Total)		57.79%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
(First 15 Months)		61.62%	R	R	Reported
(15 Months-30 Months)		67.12%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
(Total)		50.92%	R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
(Total)		29.72%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Acute Hospital Utilization (AHU)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
DTaP		69.03%	R	R	Reported
IPV		83.48%	R	R	Reported
MMR		85.32%	R	R	Reported
Hib		83.14%	R	R	Reported
Hepatitis B		84.59%	R	R	Reported

VZV		84.19%	R	R	Reported
<i>Pneumococcal Conjugate</i>		68.61%	R	R	Reported
<i>Hepatitis A</i>		83.48%	R	R	Reported
<i>Rotavirus</i>		67.33%	R	R	Reported
<i>Influenza</i>		30.43%	R	R	Reported
<i>Combo 3</i>		60.61%	R	R	Reported
<i>Combo 7</i>		52.69%	R	R	Reported
<i>Combo 10</i>		23.47%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
<i>Meningococcal</i>		84.13%	R	R	Reported
<i>Tdap</i>		84.78%	R	R	Reported
<i>HPV</i>		36.12%	R	R	Reported
<i>Combination 1</i>		83.39%	R	R	Reported
<i>Combination 2</i>		35.76%	R	R	Reported
Breast Cancer Screening (BCS-E)					
<i>(Total)</i>		43.77%	R	R	Reported
Documented Assessment After Mammogram (DBM-E)					
<i>Documented Assessment After Mammogram</i>		0.00%	R	R	Reported
Follow-Up After Abnormal Mammogram Assessment (FMA-E)					
<i>Follow-Up After Abnormal Mammogram Assessment</i>			NQ	NQ	Not Required
Cervical Cancer Screening (CCS-E)					
<i>Cervical Cancer Screening</i>		45.57%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
<i>(Total)</i>		38.87%	R	R	Reported
Blood Pressure Control for Patients With Hypertension (BPC-E)					
<i>Blood Pressure Control for Patients With Hypertension</i>		44.31%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
<i>Initiation Phase</i>		49.76%	R	R	Reported
<i>Continuation and Maintenance Phase</i>		64.22%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
<i>Blood Glucose Testing (Total)</i>		60.71%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		37.56%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		36.52%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening (Total)</i>		7.11%	R	R	Reported
<i>Follow-Up on Positive Screen (Total)</i>		69.28%	R	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of PHQ-9-Total (Total)</i>		8.04%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Follow-Up PHQ-9 (Total)</i>		38.78%	R	R	Reported
<i>Depression Remission (Total)</i>		10.20%	R	R	Reported
<i>Depression Response (Total)</i>		14.29%	R	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening (Total)</i>		1.78%	R	R	Reported
<i>Alcohol Counseling or Other Follow-Up Care (Total)</i>		0.00%	R	R	Reported
Adult Immunization Status (AIS-E)					
<i>Influenza (Total)</i>		17.16%	R	R	Reported
<i>Td/Tdap (Total)</i>		43.00%	R	R	Reported
<i>Zoster (Total)</i>		13.17%	R	R	Reported
<i>Hepatitis B (Total)</i>		3.31%	R	R	Reported
<i>Pneumococcal (65+)</i>		55.43%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Influenza</i>		29.24%	R	R	Reported
<i>Tdap</i>		63.92%	R	R	Reported
<i>Combination</i>		26.46%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Depression Screening</i>		13.16%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		48.08%	R	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Depression Screening</i>		14.71%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		47.19%	R	R	Reported
Social Need Screening and Intervention (SNS-E)					
<i>Food Screening (Total)</i>		0.97%	R	R	Reported
<i>Food Intervention (Total)</i>		2.08%	R	R	Reported
<i>Housing Screening (Total)</i>		1.68%	R	R	Reported
<i>Housing Intervention (Total)</i>		0.00%	R	R	Reported
<i>Transportation Screening (Total)</i>		0.74%	R	R	Reported
<i>Transportation Intervention (Total)</i>		0.00%	NA	R	Reported